The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
Lessons learned from a decade of higher-risk MDS trials
Maximilian Stahl, MD, Yale Cancer Center, New Haven, CT, reviews why combination trials in higher-risk myelodysplastic syndromes (MDS) have failed to improve on hypomethylating agent monotherapy. Dr Stahl highlights the heterogeneity of blast burden and the dual problem of dysplasia and proliferation, the risk of overlooking early toxicity signals, the need for dedicated trials in TP53-inactivated MDS, and how the 2006 response criteria can overestimate or underestimate benefit compared with the 2023 criteria. This presentation took place at the 4th International Workshop on Myelodysplastic Syndromes & Myeloproliferative Neoplasms (iwMDS/iwMPN) 2026, held in Washington, DC.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
